Phuturdex › Diseases › Metastasis
Drugs in development · updated 30 October 2026
Metastasis: drugs in development
As of 30 October 2026 there are 527 active clinical trials (recruiting or ongoing, phases I–III) on 493 drugs for metastasis. 307 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 307 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PembrolizumabKEYTRUDA, MK-3475 | II–III | 83 | NCT04534205 |
| GemcitabineGemcitabin, Gemzar | II–III | 35 | NCT06783140 |
| PaclitaxelTaxol, Paxlitaxel | III | 33 | NCT07213804 |
| CarboplatinCarboplatine, Paraplatin | III | 31 | NCT07869836 |
| NivolumabOpdivo, ONO-4538 | II–III | 30 | NCT06581406 |
| CisplatinCis Platinum, Cisplatine | II–III | 26 | NCT06783140 |
| IrinotecanOnivyde, CPT-11 | III | 21 | NCT06897644 |
| Nab-paclitaxelAbraxane, Nab-placlitaxel | III | 21 | NCT06103864 |
| Bevacizumabavastin, MVASI | III | 19 | NCT07213804 |
| PemetrexedAxtle®, Pemfexy® | III | 19 | NCT06119581 |
| CapecitabineXeloda, Capectitabine Tablets | II–III | 17 | NCT06719479 |
| Trastuzumab deruxtecanDS-8201a, DS-8201 | III | 17 | NCT04784715 |
| FulvestrantCligavyx®, Faslodex® | II–III | 16 | NCT06506955 |
| CetuximabErbitux | III | 15 | NCT06064877 |
| DocetaxelTaxotere, Beizray® | II–III | 15 | NCT04787744 |
Sorted by most advanced phase and number of active trials. Showing 15 of 186 drugs.
All 493 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Lymphatic metastasis 13 drugs
- Neoplasms, Unknown Primary 10 drugs
- Circulating tumor cell 9 drugs
- Breast neoplasm 593 drugs
- Triple-negative breast neoplasm 334 drugs
- Renal cell carcinoma 228 drugs
- Cholangiocarcinoma 136 drugs
- Uterine cervix neoplasm 224 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Sarcoma 204 drugs
- Transitional cell carcinoma 146 drugs
- Thyroid neoplasm 99 drugs
Broader categories
- Neoplastic Processes 7 drugs
- Neoplasm 671 drugs
- Digestive System Diseases 36 drugs
- Digestive system neoplasm 37 drugs
- Glandular and epithelial neoplasm 12 drugs
- Skin and connective tissue diseases 3 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009362 “Neoplasm Metastasis”.